뒤로
Adaptimmune Therapeutics PLC(ADAP) 가격
ADAP 주가 차트
ADAP 재무
Adaptimmune Therapeutics PLC
$0.04
-3%
$0
종가: Feb 12, 16:00:00 GMT-5
$0.04
0%
$0
애프터마켓: Feb 12, 20:00:00 GMT-5
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
ADAP 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
Adaptimmune Therapeutics PLC의 주요 재무제표는 무엇인가요?
ADAP의 주요 재무 비율은 무엇인가요?
Adaptimmune Therapeutics PLC의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Adaptimmune Therapeutics PLC은 수익성이 있나요?
Adaptimmune Therapeutics PLC에 부채가 있나요?
Adaptimmune Therapeutics PLC의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$0.05
시가
$0.0425
일일 범위
$0.0425 - $0.0599
52주 범위
$0.0009 - $0.6214
거래량
1.6M
평균 거래량
32.8M
EPS(TTM)
-0.11
배당수익률
--
시가총액
$12.8M
ADAP란 무엇인가요?
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.